DiaActive protocol: A randomized controlled trial of cognitive-motor multicomponent exercise to reduce fall rate in older adults with diabetes
- Journal
- Diabetic medicine : a journal of the British Diabetic Association (Q1)
- Published
- 30 August 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Aksayan Arunanthy Mahalingasivam, Asger Ahlmann Bech, Peter Vestergaard, Martin Grønbech Jørgensen, Nicklas Højgaard-Hessellund Rasmussen
- PMID
- 42669212
- DOI
- 10.1111/dme.70461
Why clinicians should know about it
- Picked for Internal Medicine (top studies of the week, 6 September 2026): Fall prevention trial relevant for older acute patients
Abstract
INTRODUCTION: Older adults with diabetes have an increased risk of falls due to neuropathy, impaired bone health and cardiovascular disease, resulting in significant morbidity and mortality. Conventional fall-prevention programmes primarily target strength and balance, while cognitive-motor integration, essential for safe mobility in complex environments, is often overlooked. Multicomponent exercise combining physical and cognitive training may therefore provide additional benefits in this population. METHODS: The DiaActive trial is a single-centre, stratified, parallel-group randomized controlled trial including adults aged ≥65 years with type 1 or type 2 diabetes. After comprehensive baseline assessments, 440 participants (220 with type 1 diabetes and 220 with type 2 diabetes) with low-to-moderate fall risk are randomized 1:1 within diabetes type to a 26-week cognitive-motor multicomponent exercise intervention (RYMA) or usual care. The intervention includes two weekly supervised sessions combining rhythm-based motor training with activities-of-daily-living-focused strength and balance exercises. RESULTS: The primary outcome is fall rate during the intervention, assessed using weekly fall calendars. Secondary outcomes include balance performance, fall-related outcomes, bone mineral density, fractures, neuropathy progression, cardiovascular risk markers, muscle strength and cognitive function. Follow-up continues to 104 weeks, with registry-based outcomes assessed at 5 years. CONCLUSION: The trial is approved by the North Denmark Region Ethics Committee (N-20240025). Written informed consent will be obtained. Results will be disseminated through peer-reviewed publications, conferences and stakeholder engagement.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.